In its report, Dom Maklerski BOŚ recommends the purchase of Pure Biologics shares. It indicates that proprietary platforms and the current, high co-financing of projects are a great competitive advantage. According to analysts, we fit perfectly into global trends and a broad portfolio of projects at various stages of development increases the chances of success.
This is the first analysis and recommendation since Pure Biologics entered the main floor of the Warsaw Stock Exchange.
Artykuł: 📰 Pure Biologics: Potencjał ukryty w projektach (🇵🇱)